Tilray, a Global Leader in Medical Cannabis, Announces Expansion of Premium Craft Cannabis Production at its Advanced EU-GMP Facility in Germany; Tilray Medical Enhances Tilray Craft Cannabis Portfolio with New Patient-Centered Offerings
Tilray (NASDAQ: TLRY) has announced the expansion of its Tilray Craft premium cannabis portfolio in Germany with five new cannabis flower products. These products will be produced at the company's EU-GMP certified facility in Neumünster, Germany as part of the BfArM in-country cultivation program.
The new offerings include various THC concentrations ranging from THC22 to THC30, featuring strains such as Triangle Mints, Platinum Pave 34, and Sunset Sherbet. All products will be available by prescription at German pharmacies, adhering to rigorous quality control standards and protocols to ensure consistency and reliability for patients.
Tilray (NASDAQ: TLRY) ha annunciato l'espansione del suo portafoglio premium Tilray Craft cannabis in Germania con cinque nuovi prodotti di fiori di cannabis. Questi prodotti saranno prodotti presso l'impianto certificato EU-GMP a Neumünster, Germania, nell'ambito del programma di coltivazione interno BfArM.
Le nuove offerte includono diverse concentrazioni di THC che variano da THC22 a THC30, presentando varietà quali Triangle Mints, Platinum Pave 34 e Sunset Sherbet. Tutti i prodotti saranno disponibili su prescrizione nelle farmacie tedesche, conformi a rigorosi standard di controllo della qualità e protocolli per garantire coerenza e affidabilità per i pazienti.
Tilray (NASDAQ: TLRY) ha anunciado la expansión de su cartera premium Tilray Craft de cannabis en Alemania con cinco nuevos productos de flores de cannabis. Estos productos se producirán en la instalación certificada EU-GMP en Neumünster, Alemania de la empresa, como parte del programa de cultivo en el país de BfArM.
Las nuevas ofertas incluyen varias concentraciones de THC que van desde THC22 hasta THC30, con variedades como Triangle Mints, Platinum Pave 34 y Sunset Sherbet. Todos los productos estarán disponibles con receta en las farmacias alemanas, cumpliendo con estándares rigurosos de control de calidad y protocolos para garantizar consistencia y fiabilidad para los pacientes.
Tilray (NASDAQ: TLRY)가 독일에서 Tillray Craft 프리미엄 대마초 포트폴리오를 다섯 가지 새로운 대마초 꽃 제품으로 확장했다고 발표했습니다. 이 제품들은 독일 Neumünster의 EU-GMP 인증 시설에서 생산되며 BfArM 내 국내 재배 프로그램의 일환으로 생산됩니다.
새로운 제품은 THC22에서 THC30까지 다양한 농도를 포함하며 Triangle Mints, Platinum Pave 34, Sunset Sherbet 같은 품종을 특징으로 합니다. 모든 제품은 독일 약국에서 처방으로 구매 가능하며, 환자의 일관성과 신뢰성을 보장하기 위해 엄격한 품질 관리 표준과 프로토콜을 준수합니다.
Tilray (NASDAQ: TLRY) a annoncé l’expansion de son portefeuille premium Tilray Craft de cannabis en Allemagne avec cinq nouveaux produits de fleurs de cannabis. Ces produits seront fabriqués dans l’installation certifiée EU-GMP à Neumünster, Allemagne de l’entreprise, dans le cadre du programme de culture sur le territoire BfArM.
Les nouvelles propositions comprennent diverses concentrations de THC allant de THC22 à THC30, avec des variétés telles que Triangle Mints, Platinum Pave 34 et Sunset Sherbet. Tous les produits seront disponibles sur ordonnance dans les pharmacies allemandes, conformément à des normes de contrôle qualité rigoureuses et à des protocoles visant à assurer la cohérence et la fiabilité pour les patients.
Tilray (NASDAQ: TLRY) hat die Erweiterung seines Tilray Craft Premium-Cannabis-Portfolios in Deutschland angekündigt, mit fünf neuen Cannabisblüten-Produkten. Diese Produkte werden in der EU-GMP-zertifizierten Anlage in Neumünster, Deutschland hergestellt, im Rahmen des BfArM-In-Country-Anbauprogramms.
Die neuen Angebote umfassen verschiedene THCs-Konzentrationen von THC22 bis THC30 und enthalten Sorten wie Triangle Mints, Platinum Pave 34 und Sunset Sherbet. Alle Produkte werden in deutschen Apotheken verschreibungspflichtig erhältlich sein und dabei strenge Qualitätskontrollstandards und Protokolle einhalten, um Konsistenz und Zuverlässigkeit für Patienten zu gewährleisten.
Tilray (NASDAQ: TLRY) أعلنت عن توسيع محفظة Tilray Craft القنب المميزة في ألمانيا مع خمسة منتجات زهور قنب جديدة. ستُنتج هذه المنتجات في منشأة EU-GMP المعتمدة في نويمنستر، ألمانيا كجزء من برنامج الزراعة داخل البلد للبفأرم (BfArM).
تشمل العروض الجديدة طيفا من تركيزات THC تتراوح من THC22 إلى THC30، وتضم سلالات مثل Triangle Mints، Platinum Pave 34، Sunset Sherbet. ستكون جميع المنتجات متوفرة بوصفة طبية في الصيدليات الألمانية، مع الالتزام بمعايير رقابة جودة صارمة وبروتوكولات لضمان الاتساق والموثوقية للمرضى.
Tilray (NASDAQ: TLRY) 宣布在德国扩展其 Tilray Craft 高端大麻产品组合，推出 五款新的大麻花朵产品。这些产品将于公司在德国纽明斯特的 EU-GMP 认证设施 内生产，作为 BfArM 境内栽培计划的一部分。
新产品系列包含从 THC22 至 THC30 的多种 THC 含量，特色品种包括 Triangle Mints、Platinum Pave 34、Sunset Sherbet 等。所有产品将可在德国药房凭处方购买，遵循严格的质量控制标准和协议，以确保对患者的一致性和可靠性。
- None.
- None.
Insights
Tilray strengthens German position by expanding locally-produced medical cannabis offerings, bolstering EU market leadership while meeting strict regulatory standards.
Tilray's expansion of its Craft cannabis portfolio in Germany represents a strategic strengthening of its European medical cannabis position. The company is adding five new cannabis flower products to its German product line, all cultivated at their EU-GMP certified facility in Neumünster as part of Germany's official in-country cultivation program (BfArM).
This move demonstrates Tilray's continuing investment in its German production infrastructure, allowing the company to vertically integrate its operations while meeting the stringent EU-GMP pharmaceutical standards required in the German medical market. By producing locally, Tilray gains several advantages: reduced supply chain complexity, potentially improved margins by eliminating import-related costs, and strengthened relationships with German healthcare stakeholders.
The new Tilray Craft products feature carefully controlled THC potencies ranging from 22% to 30%, offering physicians precise dosing options to match patient needs. The portfolio expansion includes specific cannabis genetics (Triangle Mints, Platinum Pave 34, and Sunset Sherbet), allowing for more tailored treatment approaches—a significant benefit in a medically-focused market where consistency and reliability are paramount.
What's particularly notable is that these products are part of Germany's tightly controlled domestic cultivation program, which gives Tilray a competitive advantage as one of the few companies authorized to grow medical cannabis within German borders. As Germany continues developing its medical cannabis framework, Tilray's established EU-GMP compliant production capabilities position the company to capture market share in one of Europe's most important medical cannabis markets.
NEUMÜNSTER, Germany, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tilray Medical a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY) and a global leader in medicinal cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, transforming healthcare today announced the expansion of its Tilray Craft portfolio in Germany with five new cannabis flower products produced in Germany at Tilray’s EU‑GMP certified facility in Neumünster as part of the BfArM in‑country cultivation program. The additions reflect Tilray’s ongoing commitment to providing physicians and pharmacies with a diverse range of quality, EU‑GMP certified medical cannabis options for eligible patients.
Rajnish Ohri, Managing Director International at Tilray Brands, commented, “The expansion of our Tilray Craft premium cannabis flower range demonstrates our commitment to patient care in Germany. As a global leader in medical cannabis, supported by our advanced EU-GMP facility in Germany, Tilray continuously introduces new genetics bred to pharmaceutical standards at Neumünster. This approach enables us to provide reliable, patient-focused medical cannabis options. Our priority remains delivering consistent, quality solutions to physicians and pharmacies, always placing patients' needs first.”
Tilray Craft cannabis is cultivated and produced indoors at Tilray’s EU‑GMP certified facility located in Neumünster, Germany. The production process adheres to rigorous quality control standards and protocols, ensuring distinctive, quality medical cannabis that patients can depend on for consistency and reliability.
New Tilray Craft Products:
- Tilray Craft Cannabisblüten THC30 TRM (Triangle Mints)
- Tilray Craft Cannabisblüten THC28 TRM (Triangle Mints)
- Tilray Craft Cannabisblüten THC28 PPV (Platinum Pave 34)
- Tilray Craft Cannabisblüten THC25 PPV (Platinum Pave 34)
- Tilray Craft Cannabisblüten THC22 SNS (Sunset Sherbet)
All Tilray Craft products are available by prescription at pharmacies throughout Germany. Tilray remains dedicated to advancing medical cannabis innovation and supporting healthcare professionals with quality, compliant solutions. As patient needs continue to evolve, the company will responsibly expand its portfolio to ensure access to consistent, EU-GMP certified products both within Germany and internationally.
About Tilray Craft
Tilray Craft is next-level quality. It’s our specialist range of high potency flower exclusive to German patients. Indoor-grown in Neumünster, we focus on precision, optimising every stage of the process so that we bring patients only our very best buds. Combined with carefully selected, high THC, unique terpene genetics, Tilray Craft is fast becoming the medical cannabis brand of choice for higher-strength therapy needs.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray Medical, Tilray Craft, Broken Coast, Redecan, Good Supply and Navcora. Tilray Medical grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Portugal and Germany. Today, Tilray Medical is a leading supplier of medical cannabis with a portfolio of brands and products designed to meet the needs of our patients worldwide.
For further information on Tilray Medical, visit Tilray Medical Europe, Tilray Medical Canada, and Tilray Medical Australia-New Zealand.
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, New Zealand and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.
For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.
For further information:
Media: news@tilray.com
Investor Relations: investors@tilray.com
FAQ
What new products did Tilray (TLRY) announce for the German market in September 2025?
Where will Tilray produce its new Craft cannabis products in Germany?
How can patients in Germany access Tilray's new Craft cannabis products?
What quality standards are applied to Tilray's new German cannabis products?
